"Duloxetine Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA.
| Descriptor ID |
D000068736
|
| MeSH Number(s) |
D02.886.778.260 D03.383.903.260
|
| Concept/Terms |
Duloxetine- Duloxetine
- N-methyl-3-(1-naphthalenyloxy)-3-(2-thiophene)propanamide
- N-methyl-3-(1-naphthalenyloxy)-2-thiophenepropanamine
|
Below are MeSH descriptors whose meaning is more general than "Duloxetine Hydrochloride".
Below are MeSH descriptors whose meaning is more specific than "Duloxetine Hydrochloride".
This graph shows the total number of publications written about "Duloxetine Hydrochloride" by people in this website by year, and whether "Duloxetine Hydrochloride" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2008 | 0 | 3 | 3 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Duloxetine Hydrochloride" by people in Profiles.
-
Duloxetine may have clinical value: comment on the article by van den Driest et al. Arthritis Rheumatol. 2022 11; 74(11):1859-1860.
-
A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology. 2015 Jul; 40(8):2025-37.
-
Duloxetine-induced tako-tsubo cardiomyopathy: implications for preventing a broken heart. South Med J. 2011 May; 104(5):303-4.
-
Duloxetine for the treatment of generalized social anxiety disorder: a preliminary randomized trial of increased dose to optimize response. CNS Spectr. 2010 Jul; 15(7):367-73.
-
Open-label support for duloxetine for the treatment of panic disorder. CNS Neurosci Ther. 2009; 15(1):19-23.
-
Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. Hum Psychopharmacol. 2008 Aug; 23(6):519-26.
-
Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. J Psychiatr Res. 2008 Oct; 42(14):1176-84.
-
Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. J Psychiatr Res. 2008 Oct; 42(12):1042-9.
-
SNRIs in the management of acute major depressive disorder. J Clin Psychiatry. 2004; 65 Suppl 17:11-8.